MarketPR
MARKETSCatalyst Bancorp (CLST) closes Lakeside Bancshares acquisitionJul 18MARKETSMercantile Bank subsidiary crosses 500 affordable housing units financed in MichiganJul 18MARKETSQuickLogic (QUIK) and PQSecure pair on reprogrammable post-quantum security for SoCsJul 18MARKETSClass action names Nano-X Imaging and certain officers, putting NNOX in focusJul 18MARKETSS&P Dow Jones Indices and MSCI open investment community consultation on GICS changesJul 17MARKETSPomerantz LLP class action against Verra Mobility puts VRRM investors on notice ahead of upcoming deadlinesJul 17MARKETSNNI earnings date set: Nelnet targets August 6 post-close for second-quarter printJul 17$BTCAmerican Bitcoin Corp. schedules Q2 2026 earnings release, $BTC accumulation thesis heads to the tapeJul 17MARKETSFTX Recovery Trust schedules fifth creditor distribution of approximately $900 million for July 31Jul 17MARKETSTME sets August 11 date for second-quarter 2026 earningsJul 17MARKETSCatalyst Bancorp (CLST) closes Lakeside Bancshares acquisitionJul 18MARKETSMercantile Bank subsidiary crosses 500 affordable housing units financed in MichiganJul 18MARKETSQuickLogic (QUIK) and PQSecure pair on reprogrammable post-quantum security for SoCsJul 18MARKETSClass action names Nano-X Imaging and certain officers, putting NNOX in focusJul 18MARKETSS&P Dow Jones Indices and MSCI open investment community consultation on GICS changesJul 17MARKETSPomerantz LLP class action against Verra Mobility puts VRRM investors on notice ahead of upcoming deadlinesJul 17MARKETSNNI earnings date set: Nelnet targets August 6 post-close for second-quarter printJul 17$BTCAmerican Bitcoin Corp. schedules Q2 2026 earnings release, $BTC accumulation thesis heads to the tapeJul 17MARKETSFTX Recovery Trust schedules fifth creditor distribution of approximately $900 million for July 31Jul 17MARKETSTME sets August 11 date for second-quarter 2026 earningsJul 17
NewsHealth

FDA quietly delays deadline on electric shock ban

The Food and Drug Administration pushed back a deadline connected to its proposed ban on electric shock devices, STAT News reported. The source provided no details on the affected devices, involved parties, or revised regulatory timeline.

By Callum WhyteNewsroomJuly 10, 20262 min read
Share

The Food and Drug Administration pushed back a deadline connected to its proposed ban on electric shock devices, STAT News reported. The source provided no details on the affected devices, involved parties, or revised regulatory timeline.

What to watch

The next confirmable milestone is a formal FDA rulemaking notice setting a new deadline. Until the agency publishes one, the status of the ban remains unsettled.

The source material contained no supporting figures, named parties, device specifics, or dates beyond the headline. Per this desk's standards, the piece has been kept to what the source actually establishes. A fuller filing or agency notice would support a complete report.

About this story

Filed by the newsroom of MarketPR on July 10, 2026. Source: MarketPR. Indicative figures are not investment advice.

←Back to the news index

More from the Newsroom

All stories →
01Health

Former U.S. Senators Press Congress to Treat Global Health as Strategic Asset, Citing PEPFAR's 26 Million Lives

Two former U.S. senators are urging Congress to institutionalize what they call "strategic health diplomacy" — the deliberate use of global health investment as an instrument of American national interest. Writing through the Bipartisan Policy Center, they point to PEPFAR, the Pr

Dev Okafor2 min read
02Health

New Poll: The Number of Americans Who Can Afford Quality Health Care Has Fallen

A new poll finds the share of Americans who can afford high-quality health care has declined, adding survey data to a pattern already visible in the gap between what employer-sponsored health plans promise and what patients absorb when something goes wrong. High-deductible plans

Marcus Cole2 min read
03Health

FDA Reverses Course on UniQure Huntington's Gene Therapy, Clearing Path to U.S. Approval Filing

The U.S. Food and Drug Administration has reversed its opposition to a closely watched gene therapy for Huntington's disease developed by biotech company UniQure, clearing a direct path for UniQure to file for U.S. regulatory approval. The agency's turnaround represents a meaning

Lena Park2 min read